A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A

INTERVENTION: Ascorbic acid (AA) treatment group (12 weeks oral AA (20mg/kg/day) no AA treatment group CONDITION: Charcot‐Marie‐Tooth disease 1A PRIMARY OUTCOME: An improvement in CMT neuropathy score at baseline, 4, 8 and 12 weeks thereafter. SECONDARY OUTCOME: An improvement in muscle strength and ulnar nerve conduction study at baseline, 4, 8 and 12 weeks thereafter. INCLUSION CRITERIA: 1) CMT1A patients with PMP duplications (triple gene doses) 2) Patients with normal function of main organs (heart, lung, liver and kidney) 3) Patients with no severe complications